Control of Post Prandial Blood Sugar Among the Treatment Patterns for Type 2 Diabetic Mellitus: A Retrospective Study

Malarkodi Velraj¹, G. Ragesh¹, Poripiraddy Satya Prasad²

¹Department of Pharmacognosy, School of Pharmaceutical Sciences, Vels University, Chennai, Tamil Nadu, INDIA.
²Department of Pharmacy Practice, Faculty of Pharmacy, Sri Ramachandra University, Porur, Chennai, Tamil Nadu, INDIA.

ABSTRACT

Objective: The study mainly focused on retrospective comparison between the various treatments alternatives for good control of post prandial blood sugar in Type-2 diabetic patients. Methods: A Retrospective study was done in patients with type 2 diabetes mellitus. All the in-patients either gender, of age between 18 to 80 years were included in the study. Patients with known surgical histories, known and suspected cases of allergies and pregnant woman’s were excluded from this study. Totally 120 patients was included. Result: The post-prandial blood glucose results showed that significant reduction in all groups after 3rd, 6th and 18th month of treatment as compared to first reading. When assessment between Group-A (Metformin+Acarbose) and B (Metformin+Glimepiride) express that Metformin+Acarbose (Group-A) 176.16 ± 0.62 have a better reduction in PPBS than Metformin+Glimepiride (Group-B) 190.58 ± 1.7. Conclusion: Over all, the study concludes that a combination of Metformin and Sitagliptin have a greater impact on control of post-prandial blood sugar compared to other two combinations.

Key words: Post prandial blood glucose, Diabetes mellitus, Metformin, Glimepiride and Acarbose.

INTRODUCTION

Post-meal blood glucose elevations pose a challenge to people with diabetes striving to maintain near-normal blood sugar levels. In diabetes, many epidemiological studies have shown that postprandial hyperglycemia is a contributing factor for atherosclerosis, oxidative stress, blood coagulation (increase in circulating D-dimers and prothrombin fragments) and cardiovascular mortality. Correcting the irregularities of the post-prandial state is the essential strategy for the prevention and management of cardiac diseases, particularly persons that are allied with diabetes mellitus. In the management of diabetes, health care providers usually assess glycemic control with fasting plasma glucose (FPG) and premeal glucose measurements, as well as by measuring HbA1c. Unfortunately, the majority of patients with diabetes fail to achieve their glycemic goals after the meal. Elevated postprandial glucose (PPG) concentrations may contribute to suboptimal glycemic control and cause earliest abnormalities of glucose homeostasis associated with type 2 diabetes. Early diagnosis and screening may help to improve the positive health outcomes in population. There is inadequate data to support the need for routine PPG monitoring in diabetes, except in the pregnancy state. Since self-monitoring of blood glucose increases a significant financial and personal burden for patients. It is predicted that by 2030 diabetes mellitus may afflict up to 79.4 million individuals in India. Particularly in Tamil Nadu, 4.8 million population are affected with diabetes mellitus as of now. The decision to recommend a glucose monitoring plan should be made judiciously, accompanied with specific patient education, regular review.
and modifications by the health care team. Continuous medical education programmes to the health care team may be a major step in achieving target glycemic control.

**METHODOLOGY**

**Study Design**

A Retrospective study was done in patients with type 2 diabetes mellitus. Patients divided into three groups based on the combinational therapies and the efficacy of the drugs compared between the groups. All the in-patients of either gender, of age between 18 to 80 years. Patients with past medical and medication histories included in this study. Records without proper lab parameters, deletion or addition of drugs in the above combinational therapy, surgical histories, known and suspected cases of allergies and pregnant woman’s were excluded from this study. Based on the above criteria, 120 patients were included in the study.

The details of combination drugs mentioned in the below.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Combinational Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>Metformin+Acarbose (500+25-50 mg)</td>
</tr>
<tr>
<td>Group B</td>
<td>Metformin+Glimepiride (500+1-2 mg)</td>
</tr>
<tr>
<td>Group C</td>
<td>Metformin+Sitagliptin (500+25-50 mg)</td>
</tr>
</tbody>
</table>

**RESULTS**

**DISCUSSION**

The post-prandial blood glucose results showed that significant reduction in all groups after 3rd, 6th and 18th month of treatment as compared to first reading.
tion in PPBS than Metformin+Glimepiride (Group-B) 190.58 ± 1.7 (Table 2 and Figure 2).

CONCLUSION
Over all, the study concludes that a combination of Metformin and Sitagliptin have a greater effect on control of post-prandial blood sugar compare with other two combinations. On the other hand, this study is not supporting the safety profile of these combination therapies. Further longterm studies are needed to ensure the maximum safety and efficacy of these therapies.

ACKNOWLEDGEMENT
I take this opportunity to thank all the department faculty members for their help and support to publish this article.

CONFLICT OF INTEREST
The author declare no conflict of interest.

ABBREVIATION USED

REFERENCES